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To investigate the time dependence of sodiumnitroprusside- (NPS-) induced oxidative effects, the authors study the variation of the
antioxidant enzyme CAT activity in various tissues after the administration of a single 2.5mg/kg dose of SNP or sodium chloride
(NaCl 0.9%). For each of the two dosing times (1 and 13 hours after light onset, HALO, which correspond to the beginning of diurnal
rest span and of nocturnal activity span of mice, resp.), brain, kidney, and liver tissues were excised from animals at 0, 1, 3, 6, 9, 12,
24, and 36 h following the drug administration and CAT activity was assayed. The results suggest that SNP-induced stimulation of
CAT activity is greater in all three tissues when the drug is administered at 1 HALO than at 13 HALO. Two-way ANOVA revealed
that CAT activity significantly (𝑃 < 0.004) varied as a function of the sampling time but not of the treatment in all three tissues.
Moreover, a statistically significant (𝑃 < 0.004) interaction between the organ sampling-time and the SNP treatment was revealed
in kidney regardless of the dosing time, whereas a highly significant (𝑃 < 0.0002) interaction was validated in liver only in animals
injected at 13 HALO.
1. Introduction
The use of SNP as an antihypertensive agent [1–4] in a
growing list of clinical conditions has been associated with
cyanide- (CN−-) induced toxicity [5, 6]. Moreover, previous
reports revealed that besides these released CN− ions, other
metabolites as nitric monoxide (NO) [7, 8] may also con-
tribute to the toxicity of this drug trough generation of reac-
tive oxygen species (ROS) such as superoxide ion (O
2
∙−) [5]
and hydrogen peroxide (H
2
O
2
) [9]. As for many other drugs,
side toxic effects of SNP have been reported both in experi-
mental [10–13] and in clinical [14, 15] designs. Indeed, it has
been reported that, within minutes of infusion, SNP decom-
poses into metabolites that are pharmacologically inactive
but toxicologically important [16]. Thus, one molecule of
SNP is metabolized by combination with haemoglobin to
produce one molecule of cyanmethaemoglobin and four CN
ions [17]. Despite this, there have been few reported cases of
CN− toxicity following the therapeutic administration of SNP
[18–20]. It is well established that the toxic free CN− can be
converted in vivo into the much less toxic thiocyanate (SCN)
by a ubiquitous enzyme rhodanese [21] that is present in
various tissues [22–25] of all living organisms, from bacteria
to humans [26–28]. SNP-induced oxidative damage has also
been reported [13, 29]. This phenomenon occurs when there
is an impairment of the balance between pro- and antioxidant
systems. It is well known that SNP-induced oxidative effects
are related to the release of NO thatmight be potentially toxic
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[7, 8]. Previous studies reported that high levels of NO may
interact with ROS or other molecules to generate many more
ROS that may induce lipid peroxidation (LPO) in various
tissues [30, 31], including brain, kidney, and liver. Moreover,
organisms have a wide spectrum of mechanisms to defend
against the potential oxidative damage from ROS formation,
including antioxidant molecules that directly inactivate ROS
and enzymes that metabolically convert toxic compounds
to forms that are readily excreted. Among these antioxidant
enzymes, CAT seems to play an important role by catalyzing
the rapid degradation [32, 33] of H
2
O
2
to water (H
2
O)
and oxygen (O
2
). Since there is previous evidence that
ROS are important in initiating several pathophysiological
processes, especially ischemic reperfusion injury [34, 35],
the role of antioxidant enzymes in health and disease is
under increasing investigation. Because much of this damage
occurs within cells, the antioxidant activity in tissue is
considered to be more relevant than that in plasma [36].
Thus, deficiencies compromising the capacity to detoxify
oxidant molecules such as H
2
O
2
and O
2
radicals result in
oxidant-induced denaturation of intracellular molecules and
premature destruction of target cells. Other enzymopathies
that might compromise intracellular reductive capacity have
also been described; they include abnormalities involving
glutathione peroxidase (GPx) and glutathione reductase
(GSR) activity [37, 38]. Therefore, any reduced capacity to
deal with oxidative stressmight involve diminished activity in
various antioxidant enzymes or reflect a diminished reserve
in the reductive capacity in mutant cells. Although it is
clear that antioxidants play an important role in protecting
cells, knowledge of molecular mechanisms that regulate their
expression is limited. Expression of various genes encoding
antioxidant enzymes is partly mediated by a cis-active DNA
element designated the antioxidant response element (ARE)
[39]. Thus, it is believed that the increase in cell sensi-
tivity results from decreased expression of oxidative-stress
response genes. Moreover, the report on downregulation of
glutathione-S-transferase (GST) and CAT genes in mutant
cells provides a plausible explanation for a molecular basis
of the observed sensitivity to oxidant compounds [40]. Since
it has been previously reported that CAT plays an essential
role in the detoxification of H
2
O
2
-derived radical species in
cells [41–43], a reduction in that enzyme’s activity would be
an important factor in the sensitivity of tissues to oxidative
stress. Nevertheless, it is likely that expression of a broad
set of other enzymes is also affected. Other authors revealed
that low concentrations of SNP had a prominent effect in
producing oxidative damage in platelets in comparison to
rat brain tissue [44]. Similarly, we recently revealed that a
neurotoxic 2.5mg/kg dose of SNP induced LPO in brain,
kidney, and liver tissues [13], but not in erythrocytes [45].
Therefore, any variation of oxidative damage among organs
might be related to their respective sensitivity and/or antioxi-
dant system efficiency. For that and since we previously found
that these three tissues showed different sensitivity to SNP-
induced LPO [13], the potentiality and efficiency of their
antioxidant systems deserve to be investigated. Hence, we
were interested in examining the effects of SNP, a well-known
NO donor, on an antioxidant enzyme CAT activity. Since
SNP also varies in potency and/or toxicity according to the
administration time [11–13, 45], the present study describes
the variation of CAT activity inmouse brain, kidney, and liver
after i.p. administration of a 2.5mg/kg dose at two circadian
times (1 and 13 HALO).
2. Materials and Methods
2.1. Animals and Housing. Male Swiss albino mice (≈25 g
body weight) aged 7–9 weeks (SIPHAT, 2013 Foundouk-
Choucha, Tunisia) were used. They were acclimated for at
least 3 weeks prior to and during experiments [46] in two-air
conditioned rooms specially designed for chronobiological
investigations by having an inverted light regimen to explore
several circadian stages during the usual diurnal work span.
In one room, the lights were on from 07:00 to 19:00 h; in
the other room, the lights were on from 19:00 to 07:00 h
(D : L 12 : 12; reversed lighting regimen). Thus, animals were
synchronized with an alternating 12 h light (L)/12 h dark (D)
cycle. The room temperature was maintained at 22 ± 2∘C
and the relative humidity was about 50–60%. During all
experiments, a standard diet (Purina Rat Chow; SICO, Sfax
3000, Tunisia) and water were provided ad libitum. Animals
were randomly divided into four different and comparable
groups of 48mice each at one of the two dosing times 1 and 13
HALO (Table 1). All experiments were performed according
to the guidelines of care and use of laboratory animals.
2.2. Drug and Animal Treatment. SNP was kindly supplied
by the National Laboratory of Drug Control (1006 Tunis,
Tunisia) in the hydrosoluble form (Na
2
[Fe(CN)
5
NO]⋅2H
2
O).
Reagents KH
2
PO
4
, K
2
HPO
4
, and H
2
O
2
(110 Vol) stock
solutions were obtained from Sigma Aldrich s.r.l. (Milano,
Italy) and Merck (Darmstadt, Germany) and were of the
highest commercial grade available. Substrate solutions were
prepared with distilled water immediately before use. Based
on our previous experience with SNP in chronotoxicological
studies, in adult mice, neurotoxic effects of SNP were trig-
gered with doses ranging from 2.5 to 5mg/kg-a median toxic
dose TD
50
(dose inducing 50%motor-inco-ordination) equal
to 3.6 ± 0.5mg/kg. Since oxidative effects of SNP seem to be
related to its neurotoxicity, the lowest neurotoxic SNP dose
(of 2.5mg/kg) was used to investigate SNP-induced oxidative
effects.
SNP was freshly prepared on each dosing time of the
study by adding an adequate volume of sterile distilled water
to obtain the desired concentration. For animal experiments,
the particular recommendations and approval of protocols
were obtained. A single 2.5mg/kg dose of SNP was admin-
istrated to mice by i.p. route in a fixed fluid volume (10mL/kg
b.w.) at each of the two circadian times (1 and 13HALO). Each
circadian time involved different but comparable subgroups
of mice (𝑛 = 6) corresponding to animals sacrificed by
decapitation at 0, 1, 3, 6, 9, 12, 24, and 36 h after injection.
Thereafter, brain, kidney, and liver tissues were quickly
removed and individually categorized with respect to tissue,
dosing-time, and sampling-time and then stored frozen at
−84∘C until assayed.
Journal of Drug Delivery 3
Table 1: Main characteristics of the study investigating chronotoxicity of SNP in male Swiss albinomice.
Drugs Doses Number of mice Dosing-time (HALO) Toxicity variable Time-of-sampling (HALO)
NaCl solution (control) 0.9% 48 1 CAT 0, 1, 3, 6, 9, 12, 24, 36
SNP 2.5mg/kg 48
NaCl solution (control) 0.9% 48 13 CAT 0, 1, 3, 6, 9, 12, 24, 36
SNP 2.5mg/kg 48
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Figure 1: Time course of CAT activity in the brain ofmice treated by i.p. routewith SNP (2.5mg/kg) orNaCl (0.9%). (a)Micewere treatedwith
SNP or NaCl at 1 HALO. (b) Mice were treated with SNP or NaCl at 13 HALO. Data are expressed as mean ± SEM values from six different
experiments in quadruplicate. The black bar corresponds to the dark period. Unpaired Student’s t-test revealed statistically significance:
∗
𝑃 < 0.01. Two-way ANOVA: time of sampling ((a) 𝐹
0.05(7,88)
= 4.8; 𝑃 < 0.004; (b) 𝐹
0.05(7,88)
= 5.9; 𝑃 < 0.002); treatment ((a) NS; (b) NS);
time-treatment interaction ((a) NS; (b) NS).
2.3. Assay Procedure of CAT Activity. For each animal, whole
brain, kidneys, and a portion of liver were separately homog-
enized (5%, w/v) in 20 vol. cold phosphate buffer (10mM
KH
2
PO
4
–10mM K
2
HPO
4
, pH 7.0) using a Petri dish main-
tained in finely crushed ice. CAT activity was determined at
room temperature (26–28∘C) as described by Claiborne [33].
This method was previously used by the authors to explore
temporal variations of CAT activity in brain, kidney, and liver
of mice in nonstress conditions [47]. Prior to the measure-
ment of enzyme activity, we demonstrated that the enzyme
followed accepted chemical principles by determining the
rates of enzyme activity.The rate (𝑅 = 1/time) of CAT activity
corresponds to the inverse of length of time (in minutes) for
O
2
gas formation (visibly apparent as bubbling) after H
2
O
2
decomposition. We noticed a linear relationship between
activity and enzyme concentration. However, according to
day, the CAT activity went linearly down by a very small
amount. The reaction mixtures (1.95mL) consisted of 10mM
solution buffer, 100mM H
2
O
2
, and a sample. The reaction
was initiated by the addition ofH
2
O
2
and absorbance changes
weremeasured at 240 nm.One unit of CAT activity is defined
as the amount of enzyme that decomposes 1mmol H
2
O
2
per
minute. All the results were given as𝜇molH
2
O
2
/min/g tissue.
In addition, we assessed the precision of measurements by
repeated assay of pools of homogenates that correspond to
each tissue. The mean imprecision (coefficient of variation:
CV) for within-sample repeatability (intra-assay, 𝑛 = 4) and
sample-to-sample reproducibility (interassay, 𝑛 = 6) was
calculated to test whether the variance or the relative SD (CV)
was relatively constant between the three studied tissues. The
mean CV within-assay was 6.9%, 7.1%, and 8.1% for liver,
kidney, and brain, respectively. The mean CV among-assay
(inter-assay) was 13.8% for liver, 14.3% for kidney, and 15.2%
for brain.
2.4. Statistical Analysis. In the current study, mean and
standard error of the mean (S.E.M.) were computed for each
sampling-time-point and pertinent histograms were drawn
for each circadian dosing-time.The Unpaired Student’s t-test
(InStat for MacIntosh, GraphPad Software, San Diego, CA,
USA) was used to compare treatment and control groups
at designated sampling-times. Two-way analysis of variance
(ANOVA) was used to test the significance of differences in
CAT activity from one sampling-time to the next by exam-
ining the interaction between sampling-time and treatment
on the activity levels. Difference is considered statistically
significant with a 𝑃 value of <0.05.
3. Results
The levels of CAT activity in relation to different sampling
times are illustrated in Figures 1, 2, and 3. CAT activity signif-
icantly varied according to the sampling-time in all three tis-
sues regardless of injection time (Tables 2 and 3). Brain CAT
activity significantly (Student’s t-test, 𝑃 < 0.01) increased 3 h
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Figure 2: Time course of CAT activity in the kidney of mice treated by i.p. route with SNP (2.5mg/kg) or NaCl (0.9%). (a) Mice were
treated with SNP or NaCl at 1 HALO. (b) Mice were treated with SNP or NaCl at 13 HALO. Data are expressed as mean ± SEM values
from six different experiments in quadruplicate. The black bar corresponds to the dark period. Unpaired Student’s t-test revealed statistically
significance: ∗∗𝑃 < 0.001. Two-way ANOVA: time of sampling ((a) 𝐹
0.05(7,88)
= 14.3; 𝑃 < 0.0001; (b) 𝐹
0.05(7,88)
= 4.8; 𝑃 < 0.003); treatment
((a) NS; (b) NS); time-treatment interaction ((a) 𝐹
0.05(7,88)
= 4.3; 𝑃 < 0.004; (b) 𝐹
0.05(7,88)
= 12.7; 𝑃 < 0.0002).
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Figure 3: Time course of CAT activity in the liver of mice treated by i.p. route with SNP (2.5mg/kg) or NaCl (0.9%). (a) Mice were treated
with SNP orNaCl at 1 HALO. (b)Mice were treated with SNP orNaCl at 13HALO.Data are expressed asmean± SEMvalues from six different
experiments in quadruplicate.The black bar corresponds to the dark period. Unpaired Student t-test revealed statistically significance: ∗∗𝑃 <
0.001. Two-way ANOVA: time of sampling ((a) 𝐹
0.05(7,88)
= 11.8; 𝑃 < 0.0001; (b) 𝐹
0.05(7,88)
= 10.9; 𝑃 < 0.0001); treatment ((a) NS; (b) NS);
time-treatment interaction ((a) NS; (b) 𝐹
0.05(7,88)
= 8.0; 𝑃 < 0.0002).
Table 2: Two-way ANOVA analyses of CAT activity variations in mouse brain, kidney, and liver after acute NPS (2.5mg/kg) injection at 1
HALO.
Source of variance DF Brain Kidney Liver
𝐹 𝑃 𝐹 𝑃 𝐹 𝑃
Time 7 4.8 <0.004 14.3 <0.0001 11.8 <0.0001
Treatment 1 10.4 NS 0.1 NS 1.2 NS
Interaction 7 10.7 NS 4.3 <0.004 2.0 NS
ANOVA: analysis of variance.
NS: not significant (𝑃 > 0.05).
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Table 3: Two-way ANOVA analyses of CAT activity variations in mouse brain, kidney, and liver after acute NPS (2.5mg/kg) injection at 13
HALO.
Source of variance DF Brain Kidney Liver
𝐹 𝑃 𝐹 𝑃 𝐹 𝑃
Time 7 5.9 <0.002 4.8 <0.003 10.9 <0.0001
Treatment 1 10.9 NS 0.2 NS 8.2 NS
Interaction 7 11.0 NS 12.7 <0.0002 8.0 <0.0002
ANOVA: analysis of variance.
NS: not significant (𝑃 > 0.05).
following the SNP (2.5mg/kg, i.p.) administration at 1 HALO
whereas the enzyme activity remained stable for the group
injected at 13 HALO, regardless of sampling time (Figure 1).
There was increased renal CAT activity 1 h after the SNP
administration at 1 HALO (𝑃 < 0.001), whereas the drug
significantly (𝑃 < 0.001) increased renal CAT activity 6 h
after injection at 13 HALO (Figure 2). Hepatic CAT activity
showed a statistically significant (𝑃 < 0.001) increase at
3 h after i.p. dosing regardless of the time of SNP injection
(Figure 3). Two-way repeatedmeasures ANOVA showed that
CAT activity varied as a function of organ sampling-time
(𝑃 < 0.003) but not of drug treatment (Tables 2 and 3).
Nonetheless, a significant (Tables 2 and 3) interaction was
detected between sampling-time and treatment in kidney and
liver tissues. This interaction was not significant in brain
tissue (Tables 2 and 3).
4. Discussion
The toxic side effects of antihypertensive drugs, including
SNP, may be multifaced and various. These potential draw-
backs that might evolve from the loss of cell viability due to
the oxidative injurymay exhibitmarked variationwith regard
to biological administration time [11–13, 45, 48, 49]. The
data presented here clearly showed that SNP administration
increased the activity of the antioxidant enzyme CAT in
a time-dependent manner in all studied tissues. Moreover,
SNP-induced oxidative damage has been reported in various
experimental [13, 45, 50] and clinical settings [51]. Paul and
Ekambaram [10] reported that the administration of similar
2.5mg/kg dose of SNP used in our study induced oxidative
stress by increasing NO concentration in brain tissue. Several
other experimental studies on NO-induced oxidative injury
showed a dependence on both cellular redox status and cell-
type specificity [13, 45, 52].The redox status is controlled by a
wide spectrumof intracellular antioxidant systems, with CAT
strongly contributing to reduce ROS levels by scavenging
H
2
O
2
that is considered as the main ROS. Our present
findings, which are in agreement with our previous studies
[13], confirmed the oxidative effects of SNP as evidenced by
the observed increase of CAT activity in all tissues studied
here. The present study showed the importance of SNP
administration time on the activity of the antioxidant enzyme
CAT. Our results showed that CAT activity, after a single dose
administration of SNP inmice, was stimulated themost when
the drug was dosed at 1 than at 13 HALO.The enzyme activity
significantly increased at 3 h for brain, 1 h for kidney, and
3 h for liver after the drug administration at 1 HALO. This
parameter remained unchanged for brain but significantly
increased at 6 h for kidney and 3 h for liver after the SNP
administration at 13 HALO. These observations suggest that
NO may be one of the critical factors in regulating cellular
redox in conditions that are associated with the production
of NO. However, the mechanism of regulation of antioxidant
enzymes byNO is not yet well established. Few in vitro studies
reported inhibitory effects of NO on antioxidant enzymes.
According to Asahi et al. [53], NO has no effect on CAT
and superoxide dismutase (CuZn-SOD and Mn-SOD) but
only inactivates GPx by modifying the cysteine-like essential
residues. On the other hand, in another study by Brown
[54], NO was found to bind CAT competing with H
2
O
2
,
causing a change in the optical absorbance spectrum of the
heme group followed by the degradation of the enzyme.
Peroxynitrite-mediated nitration on tyrosine residues and
subsequent degradation of SOD has also been reported by
Ischiropoulos et al. [55]. The results presented in this study
clearly indicate that ROS, generated through the release of
NO by SNP, increase the activity of CAT in tissues, indicating
the upregulation of expression of CATmRNA.These findings
match other scientific reports that suggest an important
role of CAT in preventing the reduction of cell viability
induced by SNP [9]. However, Lawler and Song [56] have
revealed the inhibition of CAT activity by SNP in skeletal
muscle. These authors showed that the use of a 500𝜇M SNP
dose resulted in significantly lower activities for SOD, CAT,
and GPx. Furthermore, other previous studies revealed that
SNP-induced toxicity varies in a dose-dependent fashion
and suggested that low drug doses are more cytotoxic [9].
Therefore, one hypothesis that could explain this difference
is that the dose of SNP (2.5mg/kg/10mL ≈ 840𝜇M) used in
our investigation is higher than that used by these authors.
Indeed, the use of low dose may induce the high inhibition
of CAT activity with partial reversibility, probably suggesting
an allosteric-like modification of the hem group of enzyme
[57, 58]. It has also been reported that the increase of
activities of some antioxidant enzymes by antihypertensive
drugs enalapril and captopril might protect cells against
oxidative damage [59].Thus, all two-drug treatments increase
SOD and Gpx activities, but not the CAT one. However,
intracellular events that lead to the modulation of mRNA
of antioxidant enzymes by NO or its metabolites are not
known at the present time. On the other hand, reports on the
antihypertensive drugs hydralazine and terazosin indicated
any direct inhibitor or activator effect on antioxidant enzyme
6 Journal of Drug Delivery
activities [60]. Moreover, these drugs induced the variation
in transcriptional gene levels and modulation of posttran-
scriptional process of enzymes. Other findings also revealed
that hydralazine or terazosin treatment significantly induce
changes in the levels of mRNA for SOD, CAT, and Gpx in
cardiomyocytes [61]. However, the same studies have shown
that captopril decreases the level of mRNA for hepatic SOD,
but not of CATmRNA.Moreover, two-way ANOVA revealed
a statistically significant interaction between sampling-time
and treatment on renal CAT activity regardless of the dosing
time, suggesting the influence of treatment on sampling-
time-dependent variations of the enzyme activity in this
tissue. However, this interaction observed only in the liver
of animals injected at 13 HALO was not detected in brain
tissue. It seems that the treatment-related difference was
reduced in brain compared to the kidney and liver tissues.
This difference in response to SNP-induced effects between
the three tissues may probably be related to their respective
capacities of enzymatic detoxification. Indeed, liver and
kidney are two metabolically active tissues and sites of
xenobiotic detoxification and, therefore, considered to be
ROS powerful generators [62]. Thus, the relatively high
level of CAT activities observed in these organs [47] is a
determinant factor for ROS elimination, and the tissue type
should be a factor that affects their efficiency and efficacy.Our
previous findings showed that this enzymatic detoxification
does not correlate with these damages in nonstress conditions
[47, 63]. However, the absence of temporal relation between
rhythmic patterns of CAT activity and chrono-oxidative
effects of SNP does not mean that causal relation is not
involved [64]. New investigations are needed to validate the
latter and explore the contribution of other antioxidants.
Nevertheless, the low level of MDA observed during the
dark span in the liver [13, 63] might be correlated with
the high level of CAT activity during this time [47] (see
also Figure 3), suggesting the importance of this enzyme
in liver. However, the oxidative injuries induced by SNP (a
NO donor) were variously observed according to the type of
target cells. In nucleated cells, NO may further be effective
through nitrosylation of enzymes necessary for induction of
cell membrane scrambling [65–69]. In our previous studies,
increases of LPO induced by SNP in mouse brain, kidney,
and liver tissues [13] were not evident in erythrocytes [45],
suggesting that NO released from SNP is not able to cross
the erythrocyte membrane to cause oxidative alterations.
These results demonstrate that nucleated cells (from brain,
kidney, and liver tissues) might be more sensitive to SNP-
induced LPOas compared to unnucleated erythrocytes.Thus,
since these different cells were exposed to SNP at similar
conditions, any difference in MDA levels is expected to be a
consequence of different sensitivity of tissue types. Our data
clearly show that an increase in the CAT activity by SNP
might be due to the overproduction of ROS as previously
evidenced by the observed oxidative damage in these tissues
[13]. The increase of activity of this antioxidant enzyme
suggests its protective effect by the degradation of H
2
O
2
to
prevent hydroxyl (HO∘) generation in these tissues.
In summary, the investigations carried out in the present
study provide new data to add to the study of SNP-induced
oxidative stress with reference to administration time and
type of tissue, which appeared to be closely correlated to that
of circadian variation in toxicity of SNP.
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